Nature Reviews Drug Discovery
Volume 8, No 11 November 2009
Featured Article
Can literature analysis identify innovation drivers in drug discovery?
Pankaj Agarwal & David B. Searls
Main pages for finding content:
Current issue
News
First oral therapies for multiple sclerosis anticipated
Bethan Hughes
With five novel oral therapies in late-stage development, there could soon be a wide range of treatment options for relapsing–remitting multiple sclerosis, but better biomarkers are needed to more effectively address the challenge of treating progressive forms of the disease.
Current Issue
News
Novel pharmacotherapies for obesity poised to enter market
Dan Jones
Phase III trial results for three anti–obesity therapies suggest that they meet at least some of the efficacy benchmarks for regulatory approval, although questions remain about the value of the benefits offered.
Current Issue
Review
Targeting protein kinases in central nervous system disorders
Laura K. Chico, Linda J. Van Eldik & D. Martin Watterson
The development of kinase–targeted therapies for central nervous system (CNS) diseases remains a challenge. Chico and colleagues review emerging CNS protein kinase targets and compounds in development, and discuss approaches to addressing the issues associated with CNS drug discovery, such as blood–brain barrier penetrance.
Current Issue
Research Highlights
-
Antibacterial drugs:
Proteasome target to tackle non-replicating TB
Current Issue
Review
New medicines to improve control and contribute to the eradication of malaria
Timothy N. C. Wells, Pedro L. Alonso & Winston E. Gutteridge
Wells and colleagues review the currently available antimalarials and their limitations, the contribution of genome–based technologies and in vitro screening of whole parasites to the discovery of new targets, and the issues that should be considered when developing novel antimalarials.
Current Issue
News and analysis
Influenza vaccine market dynamics
Hedwig Kresse & Holger Rovini
The threat of an influenza pandemic has stimulated considerable effort to develop improved vaccine technologies. This article analyses the key factors affecting the market for influenza vaccines.
Noticeboard
Nature Reviews Drug Discovery is now on Twitter. Follow us to keep up–to–date with the latest content.
Focus on diabetes
Although several classes of anti–diabetic drugs are available, achieving and maintaining long–term glycaemic control is often challenging, and many current agents have treatment–limiting side effects. So, a significant need for novel anti–diabetic drugs remains. This special focus highlights some of the most promising therapeutic targets and investigational drugs for type 2 diabetes and its complications, as well as discussing strategies to tackle the challenges in fulfilling their potential.
Focus on Apoptosis
Apoptosis, the major form of controlled cell death, has a key role in the pathogenesis of diseases including cancer, inflammation and neurodegenerative disorders. This special focus highlights innovative therapeutic strategies targeting apoptosis and agents in clinical trials, and discusses the challenges in realizing their potential.
Thanks to the support of Genentech, Inc., articles in the focus will be freely available until June 15 2009. Nature Publishing Group is entirely responsible for the content.
Focus on Pain
Unrelieved pain associated with conditions such as arthritis, diabetes, cancer and serious injury represents a major unmet medical need. With the aim of highlighting approaches to tackling the challenges in this field, this special collection integrates articles that discuss strategies to drive forward analgesic drug development with those that explore new targets for pain therapeutics.
Produced with support from Eli Lilly and Company, which had no control over its content.
SciBX — Ask your librarian to start a trial today!
SciBX: Science–Business eXchange is a weekly publication that identifies and analyses the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
SciBX is now available in full–text, HTML format on the nature.com platform
Recommend SciBX to your library today.
For more information visit: www.nature.com/scibx.
Focus on Antivirals
This joint Web Focus from Nature Reviews Drug Discovery and Nature Biotechnology hosts a collection of reviews, research highlights and commentaries covering the science and business of antiviral drug R&D. Thanks to the generous support of Pfizer (principal sponsor) and Gilead (supporting sponsor), content in the focus is freely available until June 2008.
PSI–Nature Structural Genomics Knowledgebase
A new window onto the world of protein structure has opened with the free PSI–Nature Structural Genomics Knowledgebase (PSI–SGKB). The site makes available the research data and tools from the Protein Structure Initiative, complemented with structural biology updates from NPG. Users can also suggest proteins for structure analysis.
Conferences
A selection of conferences in the field of drug discovery and development.
NPG BioPartnering site
This site is dedicated to small and large companies looking for commercial partnerships and finding out more about licensing.
Nature Reports Stem Cells
Nature Reports Stem Cells for the latest news, research, comment and analysis about stem cells and their implications.
Career snapshots
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Naturejobs spotlights and regions
Interactive regional map linking to information, features and career opportunities worldwide.
Natureevents
A comprehensive resource of information on scientific events and conferences around the world.
2008 Journal Citation Report (Thomson Reuters, 2009)



